
Prognostic Factors for Clinical Outcomes in Patients with PBC
This thesis, written by Dr. Carla Fiorella Murillo Perez was published January 2021. The study uses a large and globally representative cohort of patients with long-term follow-up to study various
CymaBay – Seladelpar RESPONSE Phase 3 study now enrolling
For more information see clinicaltrials.gov The following summary is provided by CymaBay Therapeutics. RESPONSE (study number CB8025-32048) is a Phase 3 clinical research study being conducted to learn more about
Elafibranor moves to Phase 3 Study called ELATIVE
The Phase 3 study will consist of Elafibranor 80mg for double blind period (52 to 104 weeks). After completion of the double blind period, participants will be offered the opportunity
EL-FIT program helps keep liver patients fit!
El-Fit offers a custom exercise program, tailored to meet the individual needs of liver patients. Using a friendly APP, the program allows patients to set goals and track progress, as
Zydus -Saroglitazar -FDA fast track designation for PBC
Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment of
CymaBay -Seladelpar Phase 3 Enhance Study shows positive results
At AASLD 2020 virtual liver conference, Dr. Gideon Hirschfield presented promising Phase 3 results for Seladelpar a treatment for patients with PBC. Positive outcomes included: 78% of those in the
Escient – upcoming clinical trial for PBC itch
There is a new clinical trial aimed at PBC pruritus. While the study is currently in New Zealand and Australia, there are plans to expand the trial to PBC patientsReal-World Effectiveness of Obeticholic Acid – new study
Obeticholic Acid was approved in Canada in May 2017, this study describes its effectiveness in two Canadian centers. Read more.
CymaBay – Seladelpar – re-initiating Phase 3 clinical trial for PBC
On November 25, 2019, CymaBay halted all clinical trials of seladelpar after atypical histologic findings with no clinical or laboratory correlates were identified at the planned end-of treatment biopsy reviewPBC Patient Guidelines
This year the PBC Network created a 36 page booklet “PBC – Living With Your Diagnosis” . The Canadian PBC Society participated in the final review of this comprehensive patient guideline and is now a proud member of the PBC Network. Read the guidelines here.